Patents Examined by Robert C. Hayes
  • Methods of measuring levels of phosphorylated neuronal nitric oxide synthase
    Patent number: 9696309
    Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injuries. In a specific embodiment, a method for diagnosing perinatal brain injury in a patient comprises the steps of (a) determining the ratio of phosphorylated nNOS to unphosphorylated nNOS in a sample collected from the patient using an ELISA; and (b) comparing the ratio with predefined ratios of the same proteins that correlate to a patient having perinatal brain injury and predefined ratios of the same proteins that correlate to a patient not having perinatal brain injury, wherein a correlation to one of the predefined ratios provides the diagnosis.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: July 4, 2017
    Assignees: The Johns Hopkins University, Kennedy Krieger Institute, Inc.
    Inventors: Irina Burd, Talaibek Borbiev, Elisabeth Nigrini, Michael Johnston
  • Methods of reducing levels of tau
    Patent number: 9696306
    Abstract: Successful CNS drug discovery requires a scalable, highly physiological neuronal model. Using directed differentiation of mouse embryonic stem (mES) cells, including mES cells isolated from a mouse model of Alzheimer's disease (AD), a highly homogeneous primary neuronal model amenable to phenotypic assays for production and synaptotoxicity of amyloid ?-peptide was developed. This model furnishes a highly physiological and AD-relevant platform suitable for high throughput small molecule and functional genetic screens, providing specific small molecule compounds identified by such screens.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: July 4, 2017
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Tae-Wan Kim, Laura Beth Johnson McIntire, Natalie Landman, Gina Finan
  • Microbial-derived chondroitin sulfate
    Patent number: 9689010
    Abstract: Described is chondroitin sulfate obtained from microbial sources, and related compositions and methods.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: June 27, 2017
    Assignees: AMANO ENZYME USA, LTD., AMANO ENZYME, INC.
    Inventors: James F. Jolly, Krzysztof Klimaszewski, Yuji Nakanishi, Hirotaka Matsubara, Tetsuya Takahashi, Kyouichi Nishio
  • Dipeptide mimetics of NGF and BDNF neurotrophins
    Patent number: 9683014
    Abstract: The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexamethylenediamine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10?9 to 10?5 M.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: June 20, 2017
    Assignee: UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII IMENI V.V.ZAKUSOVA RAMN
    Inventors: Sergey Borisovich Seredenin, Alexandrovna Tatyana Gudasheva
  • Caninized anti-NGF antibodies and methods thereof
    Patent number: 9617334
    Abstract: The present disclosure encompasses novel caninized anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotides of the invention for the treatment and/or prevention of NGF related disorders, particularly for the management of canine pain.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: April 11, 2017
    Assignee: Zoetis Services LLC
    Inventors: Lisa Marie Bergeron, Graeme Bainbridge, Steven A. Dunham, Minghua Dai
  • ProNGF mutants and uses thereof in the production of beta-NGF
    Patent number: 9617322
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: April 11, 2017
    Assignee: Wacker Chemie AG
    Inventors: Susan Lorey, Bernhard Janowski, Heiko Pultke, Daniela Kathmann, Antje Parthier, Andreas Anton
  • Splice variants of GDNF and uses thereof
    Patent number: 9579362
    Abstract: The present invention relates to Glial Cell Line-Derived Neurotrophic Factor (GDNF) protein and gene and is, in particular, directed to a novel splice variant of GDNF protein, which is encoded by a novel splice variant pre-(?)pro-GDNF, and secreted under biological regulation.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: February 28, 2017
    Inventors: Liina Nevalaita, Mart Saarma
  • Methods of preventing inflammation and treating pain using anti-NGF compositions
    Patent number: 9539324
    Abstract: This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 10, 2017
    Assignee: ALDERBIO HOLDINGS, LLC
    Inventors: Leon F. Garcia-Martinez, Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham
  • Compositions for treating multiple sclerosis
    Patent number: 9517253
    Abstract: Compositions comprising Tr1 cells directed to a multiple sclerosis associated antigen and methods for treating multiple sclerosis.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: December 13, 2016
    Assignee: TXCELL
    Inventor: Arnaud Foussat
  • Anti-NGF antibodies and their use
    Patent number: 9505829
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: November 29, 2016
    Assignee: ZOETIS BELGIUM S.A.
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
  • Anti-NGF compositions and use thereof
    Patent number: 9499611
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: November 22, 2016
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne McNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
  • Methods of treating disease-induced ataxia and non-ataxic imbalance
    Patent number: 9463190
    Abstract: Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: October 11, 2016
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Theresa A. Zesiewicz, Kelly L. Sullivan
  • Stable neural stem cell lines
    Patent number: 9465025
    Abstract: A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: October 11, 2016
    Assignee: Neuralstem, Inc.
    Inventors: Renji Yang, Karl K. Johe
  • Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
    Patent number: 9447181
    Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: September 20, 2016
    Inventors: John Powell, Duncan Casson, Mark Maginn, Wei Liu, Sandeep Dutta, Andrea Best, Jerry A. Hall
  • Survival motor neuron gene (SMN2) mRNA constructs for post-transcription regulation
    Patent number: 9394539
    Abstract: The present invention provides compounds and assays for the identification and validation of compounds for use in the treatment of spinal muscular atrophy (SMA), in which said compounds up-regulate the post-transcriptional expression of SMN1 or SMN2.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: July 19, 2016
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Sergey V. Paushkin, Anuradha Bhattacharyya, Bansri S. Furia, Meenal Patel, Love Volkova
  • Methods of using myelin basic protein peptide compositions
    Patent number: 9381234
    Abstract: The present invention relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: July 5, 2016
    Assignee: APITOPE TECHNOLOGY (BRISTOL) LIMITED
    Inventors: David Wraith, Heather Barbara Streeter
  • Methods of screening for compounds for treating muscular dystrophy using human ALPHA7 integrin mRNA translation regulation
    Patent number: 9376725
    Abstract: The present invention provides compounds and assays for the identification and validation of compounds for use in the treatment of muscular mystrophy (MD), or a form thereof, in which said compounds increase the post-transcriptional expression of a target gene (i.e., mIGF1, ITGA7, or UTRN).
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 28, 2016
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Westley J. Friesen, Nikolai Naryshkin, Meenal Patel, Charles Romfo, Yuki Tomizawa, Ellen Welch, Jin Zhuo
  • Anti-TrkA antibodies, derivatives and uses thereof
    Patent number: 9365654
    Abstract: The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognize and bind an epitope comprised in the TrkA amino acid sequence, medical uses thereof and a pharmaceutical composition comprising at least one of the above antibody, recombinant or synthetic antigen-binding fragments thereof.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: June 14, 2016
    Assignee: ROTTAPHARM BIOTECH S.R.L.
    Inventors: Lucio Claudio Rovati, Michela Visintin, Gianfranco Caselli, Gabriele Ugolini
  • Methods for treating neurological diseases comprising osmotin
    Patent number: 9352018
    Abstract: The present invention relates to a composition for preventing and treating neurological diseases, and more particularly to a composition for preventing and treating neurological diseases comprising osmotin, a health functional food composition for preventing and ameliorating neurological diseases comprising osmotin, and a method of preventing or treating neurological diseases by administering the composition.
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: May 31, 2016
    Assignee: Industry-Academic Cooperation Foundation Gyeongsang National University
    Inventors: Myeong Ok Kim, M.L Narsimhan, M.L Naseer, R.A Bressan, Dae Jin Yun, Hae Young Lee
  • Method of treating osteoarthritis with an antibody to NGF
    Patent number: 9353176
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 31, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo